1. Home
  2. ASMB vs STXS Comparison

ASMB vs STXS Comparison

Compare ASMB & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ASMB
  • STXS
  • Stock Information
  • Founded
  • ASMB 2005
  • STXS 1990
  • Country
  • ASMB United States
  • STXS United States
  • Employees
  • ASMB N/A
  • STXS N/A
  • Industry
  • ASMB Biotechnology: Pharmaceutical Preparations
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ASMB Health Care
  • STXS Health Care
  • Exchange
  • ASMB Nasdaq
  • STXS Nasdaq
  • Market Cap
  • ASMB 141.8M
  • STXS 151.3M
  • IPO Year
  • ASMB 2010
  • STXS 2004
  • Fundamental
  • Price
  • ASMB $18.86
  • STXS $2.24
  • Analyst Decision
  • ASMB Strong Buy
  • STXS
  • Analyst Count
  • ASMB 3
  • STXS 0
  • Target Price
  • ASMB $33.00
  • STXS N/A
  • AVG Volume (30 Days)
  • ASMB 29.0K
  • STXS 670.4K
  • Earning Date
  • ASMB 08-15-2025
  • STXS 08-07-2025
  • Dividend Yield
  • ASMB N/A
  • STXS N/A
  • EPS Growth
  • ASMB N/A
  • STXS N/A
  • EPS
  • ASMB N/A
  • STXS N/A
  • Revenue
  • ASMB $32,154,000.00
  • STXS $27,510,000.00
  • Revenue This Year
  • ASMB $0.04
  • STXS $29.03
  • Revenue Next Year
  • ASMB N/A
  • STXS $44.05
  • P/E Ratio
  • ASMB N/A
  • STXS N/A
  • Revenue Growth
  • ASMB 148.33
  • STXS 1.50
  • 52 Week Low
  • ASMB $7.75
  • STXS $1.54
  • 52 Week High
  • ASMB $19.93
  • STXS $2.72
  • Technical
  • Relative Strength Index (RSI)
  • ASMB 55.48
  • STXS 47.91
  • Support Level
  • ASMB $16.90
  • STXS $2.11
  • Resistance Level
  • ASMB $19.43
  • STXS $2.29
  • Average True Range (ATR)
  • ASMB 1.05
  • STXS 0.15
  • MACD
  • ASMB -0.09
  • STXS -0.01
  • Stochastic Oscillator
  • ASMB 75.38
  • STXS 23.68

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Share on Social Networks: